These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 10732398)
1. NSAIDs and the gastrointestinal tract: an update on recent progress. Silverman GJ J Am Osteopath Assoc; 1999 Aug; 99(8 Suppl):S10-3. PubMed ID: 10732398 [TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors. Peura DA Cleve Clin J Med; 2002; 69 Suppl 1():SI31-9. PubMed ID: 12086291 [TBL] [Abstract][Full Text] [Related]
3. From prostaglandin replacement to specific COX-2 inhibition: a critical appraisal. Kremer J J Rheumatol Suppl; 2000 Oct; 60():9-12. PubMed ID: 11032096 [TBL] [Abstract][Full Text] [Related]
4. The multisystem adverse effects of NSAID therapy. James DS J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S1-7. PubMed ID: 10643174 [TBL] [Abstract][Full Text] [Related]
5. Use of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors: indications and complications. Pascucci RA J Am Osteopath Assoc; 2002 Sep; 102(9):487-9. PubMed ID: 12361181 [TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract. Meyer-Kirchrath J; Schrör K Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962 [TBL] [Abstract][Full Text] [Related]
8. Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events. Freston JW Am J Med; 1999 Dec; 107(6A):78S-88S; discussion 89S. PubMed ID: 10628597 [TBL] [Abstract][Full Text] [Related]
9. [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications]. ; Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):81-85. PubMed ID: 28056333 [TBL] [Abstract][Full Text] [Related]
10. The unmet anti-inflammatory needs in orthopedics. Trippel SB Am J Orthop (Belle Mead NJ); 1999 Mar; 28(3 Suppl):3-7. PubMed ID: 10193996 [TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory effect and low ulcerogenic activity of etodolac, a cyclooxygenase-2 selective non-steroidal anti-inflammatory drug, on adjuvant-induced arthritis in rats. Tachibana M; Inoue N; Yoshida E; Matsui M; Ukai Y; Yano J Pharmacology; 2003 Jun; 68(2):96-104. PubMed ID: 12711837 [TBL] [Abstract][Full Text] [Related]
13. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. Fung HB; Kirschenbaum HL Clin Ther; 1999 Jul; 21(7):1131-57. PubMed ID: 10463513 [TBL] [Abstract][Full Text] [Related]
14. Considerations for nonsteroidal anti-inflammatory drug therapy: safety. Blower AL Scand J Rheumatol Suppl; 1996; 105():13-24; discussion 25-7. PubMed ID: 8792807 [TBL] [Abstract][Full Text] [Related]
15. Cost-effective use of NSAIDs: issues pertinent to coxib use in managed care. Fendrick AM Am J Manag Care; 2002 Nov; 8(17 Suppl):S529-41. PubMed ID: 12458822 [TBL] [Abstract][Full Text] [Related]
16. Understanding NSAIDs: from aspirin to COX-2. Green GA Clin Cornerstone; 2001; 3(5):50-60. PubMed ID: 11464731 [TBL] [Abstract][Full Text] [Related]
17. Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy. Fendrick AM Cleve Clin J Med; 2002; 69 Suppl 1():SI59-64. PubMed ID: 12086296 [TBL] [Abstract][Full Text] [Related]